In The News
Cancer Therapy Advisor – RACE Act Increases Required Pediatric Studies for Cancer Drugs
The RACE Act has successfully increased the number of pediatric clinical trials that must be conducted for cancer therapies approved in adults, according to research
SelectScience – RACE act increased the number of cancer drugs with required studies for use in pediatric patients
The Research to Accelerate Cures and Equity (RACE) for Children Act was approved by the U.S. Congress in 2017 and took effect on August 18,
Medscape – More Drugs Tested in Pediatric Cancer: RACE for Children Act
NEW ORLEANS ― Even within the first year of implementation, the Research to Accelerate Cures and Equity (RACE) for Children Act has made an impact.
Healio – RACE Act led to more required pediatric studies of cancer drugs
The Research to Accelerate Cures and Equity Act led to an increase in required pediatric studies for recently approved cancer therapies within the first year
AACR – RACE Act Increased the Number of Cancer Drugs with Required Studies for Use in Pediatric Patients
NEW ORLEANS – In its first year of implementation, the RACE Act has resulted in increased requirements for more recently approved cancer drugs to be
GlobeNewswire – Bionano Genomics Announces Release of Version 6.2 of its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis
SAN DIEGO, April 07, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of
Oncology Times – Biomarker-Driven Development of Diagnostics for Rare Diseases
Biomarker-driven cancer care relies on precision companion diagnostics co-developed with targeted therapies in clinical trials. A one-drug/one-test strategy has been the norm in such co-development.
BioSpace – Accelerated Approval Integrity Act Could Remove Therapies Before They Prove Merit
The Accelerated Approval Integrity Act of 2022 (H.R. 6963) aims to remove loopholes in the Food and Drug Administration‘s accelerated approval pathway. The bill, however, fails to adequately
The Washington Post – National Cancer Institute Director Sharpless stepping down
Norman “Ned” Sharpless, the director of the National Cancer Institute who had a short stint leading the Food and Drug Administration, announced Monday that he is stepping down
Bloomberg Law – National Cancer Institute Director Sharpless Steps Down (1)
Ned Sharpless, one of the last presidential appointees from the Trump administration to be held over by President Joe Biden’s White House, will step down
